Our Mission

The mission of PPMI is to identify one or more biomarkers of Parkinson’s disease progression. The discovery of a biomarker is a critical step in the development of new and better treatments for PD. This study is being sponsored by The Michael J. Fox Foundation for Parkinson's Research.



PPMI Enrollment Status

55%
Prodromal Participants
Enrollment Goal: 100

18%
Genetic Cohort Participants
Enrollmen Goal: 600

14%
Genetic Registry Participants
Enrollment Goal: ~600

100%
De Novo PD Participants
Enrollment Goal: 400

100%
Control Participants
Enrollment Goal: 200

100%
Subjects with SWEDD
Enrollment: 64

Last Update: January 27, 2015

 

More about study cohorts >

Welcome

Welcome to the Parkinson’s Progression Markers Initiative (PPMI), a landmark observational clinical study to comprehensively evaluate cohorts of significant interest using advanced imaging, biologic sampling and clinical and behavioral assessments to identify biomarkers of Parkinson’s disease progression.

PPMI is taking place at clinical sites in the United States, Europe, Israel, and Australia. Data and samples acquired from study participants will enable the development of a comprehensive Parkinson’s database and biorepository, which is currently available to the scientific community to conduct field-changing research.

PPMI is made possible by the concerted efforts of a number of collaborators. This study is sponsored by The Michael J. Fox Foundation for Parkinson’s Research.

Learn more about Who We Are.

LATEST NEWS FROM PPMI

2015 Sample Request Rolling Application Deadlines

Qualified researchers can request access to PPMI biospecimens through the rolling application process. Mark your calendars with the 2015 schedule to ensure timely submission and review.


Genetics Participant Study Update Call

Andrew Singleton, PhD, principal investigator of the PPMI Genetics Core at the National Institute on Aging/NIH was the latest guest speaker in the PPMI Study Update Call series for enrolled participants. You can now listen to this call about PPMI, genetics, and PD on the For Enrolled Participants page.


PPMI Biosamples Webinar Posted

PPMI’s principal investigator, Ken Marek, MD, and The Michael J. Fox Foundation’s Mark Frasier, PhD held the PPMI Progress Update: Available Data and Biosamples webinar, covering an overview of PPMI, some initial findings, and the process for accessing the PPMI clinical data, imaging data, and biospecimens. A recording of the webinar is now available.


New Serum Data Ready to Download

Serum analysis data from Maria Teresa Pellecchia, MD of the University of Salerno is now live in the PPMI database. Qualified researchers can download this data at no cost.


Webinar on Available Parkinson’s and Controls Biosamples

PPMI and The Michael J. Fox Foundation are hosting a webinar which will cover available PPMI samples and data and the process for requesting both. The webinar will take place Monday, December 15, 12 to 1 p.m. ET. Learn more and register today.


Learn More